Ko da tiyata, radiotherapy, chemotherapy, da/ko jiyya da aka yi niyya (kamar cetuximab), ƙimar rayuwa na shekaru biyar don ci gaban kansa da kansa na gida shine kawai 46%. Yawancin lokaci, magani yana da kyau a farkon, amma ci gaban ciwon daji zai iya haifar da juriya na miyagun ƙwayoyi.
Masu bincike a Cibiyar Ciwon daji ta Jami'ar Colorado sun gano cewa nau'ikan kwayoyin halitta guda biyu da ke da alaƙa da haɓakar kwakwalwar farko, amma shiru a cikin kyallen jikin manya masu lafiya yana haifar da juriya ga samfuran ƙari. Kwayar halittar ita ce EphB4 kuma kwayar halittar da ke biye ita ce ephrin-B2. Dukansu kwayoyin halitta za su tashi bayan mai haƙuri ya kasa magani, don haka za ku iya kaiwa hari don ganin ko yana da tasiri.
Don wannan, sun yi amfani da ƙwayar ƙwayar cuta daga marasa lafiya da suka dawo don girma a cikin berayen. Daga nan ne aka raba berayen zuwa kungiyoyin jiyya, wasu daga cikinsu sun sami chemotherapy cisplatin, wasu sun karbi maganin cetuximab na anti-EGFR, wasu kuma sun sami maganin radiation kadai ko ban da wadannan magunguna. Ƙara maganin hanawa na EphB4-ephrin-B2 na gwaji zuwa wata ƙungiya ta daban don kowace ƙungiya.
A cikin rukunin cisplatin, yawan amfani da ƙari na sabon maganin hana hanawa bai fito fili ba, amma ƙari na EphB4-ephrin-B2 inhibitor zuwa EGFR inhibitor cetuximab magani ya rage girman ƙwayar ƙwayar cuta, kuma an sami ƙarin ƙimar rayuwa mai kyau. Masu binciken sun yi imanin cewa EGFR da EphB4-ephrin-B2 na iya amfani da su azaman madadin hanyoyin.
Masu hana EphB4-ephrin-B2 a halin yanzu suna fuskantar gwaji na asibiti a wasu cututtukan daji. Bincikenmu ya nuna cewa ana iya samun nasarar amfani da shi tare da masu hana EGFR don maganin ciwon daji na kai da wuya. Ana iya haɗa masu hasashen EphB4-ephrin-B2 tare da masu ciwon ƙari waɗanda ke nuna manyan matakan waɗannan sunadaran.
